Literature DB >> 498071

Cellular accumulation and disposition of aclacinomycin A.

M J Egorin, R E Clawson, L A Ross, N M Schlossberger, N R Bachur.   

Abstract

The cellular accumulation and disposition of the anthracycline antitumor antibiotic aclacinomycin A (ACM) were compared to those of daunorubicin. Although both drugs were avidly accumulated by cells, intracellular concentrations of ACM were two to three times those of daunorubicin. Whereas lowered temperature (0 degrees) reduced intracellular accumulation of both drugs, 10 mM sodium azide had no effect on accumulation of either ACM or daunorubicin. Both drugs exited from cells placed in drug-free medium, a process that was reduced at 0 degrees but not altered by 10 mM sodium azide. Unlike whole cells, isolated nuclei accumulated more daunorubicin than ACM. This process was not altered at 0 degrees. Both drugs were lost from nuclei placed in drug-free buffer, a process that was reduced at 0 degrees. Unlike daunorubicin, which localized in cell nuclei, ACM localized in the cytoplasm with no detectable nuclear fluorescence. Although both drugs produced dose-dependent inhibitions of [3H]thymidine and [3H]uridine incorporation by L1210 and P388 cells, ACM inhibited both processes at lower concentrations than did daunorubicin. While daunorubicin inhibited [3H]thymidine incorporation more effectively than [3H]uridine incorporation, the reverse was observed with ACM.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498071

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  The subcellular distribution of small molecules: from pharmacokinetics to synthetic biology.

Authors:  Nan Zheng; Hobart Ng Tsai; Xinyuan Zhang; Gus R Rosania
Journal:  Mol Pharm       Date:  2011-08-15       Impact factor: 4.939

2.  Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone.

Authors:  T Yoshida; S Nakamura; S Ohtake; K Kobayashi; M Kanno; T Matsuda; S Matano; K Kondo; K Okafuji; M Kanai
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.

Authors:  A Zenebergh; R Baurain; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Plasma kinetics of aclacinomycin A and its major metabolites in man.

Authors:  M J Egorin; D Van Echo; B M Fox; M Whitacre; N R Bachur
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  In vitro and in vivo responses of a murine transitional cell carcinoma to doxorubicin, mitoxantrone and aclacinomycin-A.

Authors:  R J Ballou; M T Tseng
Journal:  Urol Res       Date:  1986

6.  Inhibition of protein kinases by anticancer DNA intercalator, 4-butylaminopyrimido[4',5':4,5]thieno(2,3-b)quinoline.

Authors:  HeggoduG Rohit Kumar; Chethan S Kumar; Hulihalli N Kiran Kumar; Gopal M Advi Rao
Journal:  Acta Pharm Sin B       Date:  2017-03-07       Impact factor: 11.413

7.  Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.

Authors:  T Yamaoka; M Hanada; S Ichii; S Morisada; T Noguchi; Y Yanagi
Journal:  Jpn J Cancer Res       Date:  1999-06

8.  Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines.

Authors:  H M Coley; W B Amos; P R Twentyman; P Workman
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.